Women enter menopause at an average age of around 50, which marks the start of a postmenopausal stretch that covers a large share of their remaining life. Yet since 2002, menopausal hormone therapy has been something millions of women avoided out of fear of cancer risk. The Women's Health Initiative (WHI) was a large trial that randomized 27,347 women in the US between 1993 and 1998 to test whether hormone therapy could prevent heart disease: 16,608 women with a uterus (estrogen-plus-progestin arm) and 10,739 women without a uterus (estrogen-only arm). When the estrogen-plus-progestin results were published in 2002, the picture was the opposite of what was expected: over a mean follow-up of 5.6 years, invasive breast cancer risk rose 24% (hazard ratio 1.24, 95% CI 1.10-1.54, p=0.003). The trial was halted immediately, the FDA added a boxed warning to hormone therapy products, and millions of women worldwide stopped treatment.
The problem was this: the average age of WHI participants was 63 — far older than the typical age at which women start hormone therapy in real life, often 10 to 20 years past menopause. A 2007 reanalysis by Manson and colleagues in JAMA, stratified by age and years since menopause, confirmed as much: coronary heart disease risk for women starting treatment within 10 years of menopause had a hazard ratio of 0.76 (95% CI 0.50-1.16), rising to 1.10 (0.84-1.45) for those starting 10-19 years later, and 1.28 (1.03-1.58) for those starting 20 or more years later — risk rose as the gap widened (trend p=0.02). By age group, the 50-59 bracket showed a near-neutral hazard ratio of 0.93 (0.65-1.33), though that age-based trend wasn't statistically significant (p=0.16). This data became the basis of the "timing hypothesis": the same treatment may carry a different cardiovascular risk profile depending on whether it starts right after menopause or years later.
The only randomized controlled trial to directly test the timing hypothesis was published in BMJ in 2012. Danish researchers split 1,006 recently postmenopausal women into hormone therapy (502 women) or no treatment (504 women). After 10 years, a composite endpoint of death, heart failure, or myocardial infarction occurred in 16 women in the treatment group versus 33 in the control group (hazard ratio 0.48, 95% CI 0.26-0.87, p=0.015). But that's a composite result — looking at death alone (15 vs. 26), the difference was not statistically significant (hazard ratio 0.57, 0.30-1.08, p=0.084). So saying "hormone therapy halves the risk of death" goes beyond what this trial's data actually shows; the trial is small (1,006 women), and what it really demonstrates is a positive trend on a composite cardiovascular endpoint.
On November 10, 2025, the FDA announced it would remove the boxed warning from menopause hormone therapy products. Following a July 2025 expert panel, FDA Commissioner Marty Makary said the existing warnings were "outdated and unnecessary," and also questioned the validity of the original 2002 WHI findings. The changes are expected to take effect within six months; the new labels will carry age-specific guidance noting that benefits may outweigh risks when therapy starts within 10 years of menopause onset or before age 60. The endometrial cancer warning stays on the label for women with a uterus using estrogen-only products. The American College of Obstetricians and Gynecologists (ACOG) welcomed the decision; some physicians have pushed back, arguing the WHI data still doesn't show more benefit than harm.
An important distinction is worth drawing here: no study we have shows hormone therapy directly extends human lifespan. The Danish trial's composite endpoint is a positive signal, but death alone wasn't statistically significant; WHI's age- and timing-stratified reanalyses are about cardiovascular disease risk, not lifespan. The protective effect on bone density and fracture risk, also shown within WHI itself, is a less contested finding in the literature, but that doesn't translate directly into "extends lifespan" either. The most honest summary we can give: the timing hypothesis suggests hormone therapy's cardiovascular risk profile may be different — and likely more favorable — when started right after menopause rather than years later, but that doesn't make it a "longevity drug." It means it should be weighed as one tool for managing health risk across the decades of postmenopausal life.
The FDA's decision isn't a call for "every woman should take hormone therapy" — it's an attempt to remove an overstated warning that was standing in the way of a personalized risk-benefit conversation. For a woman in her 50s, close to menopause, without a serious history of cancer or blood clots, that conversation can now happen on more open ground. But it's still an individual decision — family history, personal risk factors, and symptom severity are variables to weigh together with a doctor. Since the actual label changes may take up to six months to implement, it may also take doctors some time to reflect the updated guidance.
No study shows this directly. The Danish randomized trial found a positive signal on a composite cardiovascular endpoint (death plus heart failure plus heart attack), but death alone was not statistically significant. The evidence we have suggests hormone therapy may improve certain cardiovascular risk markers depending on timing — not that it extends lifespan.
The FDA announced the decision on November 10, 2025, and the label changes are expected to take effect within six months. So the actual label update could take until roughly mid-2026.
Yes, the finding itself is still considered valid. What the FDA removed was the assumption that this risk applies equally to every woman, not the risk itself. The warning still matters for women with a personal history of breast cancer or a high genetic risk.
It proposes that starting hormone therapy soon after menopause (within 10 years, or before age 60) may carry a different cardiovascular risk profile than starting years later. Reanalyses of WHI data by age and years since menopause showed a statistical trend in that direction, but this is an observational subgroup analysis, not a primary randomized comparison by design.
"Hormone therapy isn't a longevity drug — but a risk-benefit balance that went unspoken for 23 years because of an overstated fear is finally back on the table."
— Vivelong Longevity Science Team